ACE2 News and Research

RSS

NeutrobodyPlex nanobodies help monitor SARS-CoV-2 immune responses

Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.

23 Sep 2020

Bat and pangolin coronavirus structure sheds light on SARS-CoV-2 evolution

Researchers at Tsinghua University, Beijing, have conducted a study providing possible new insights into the evolution and cross-species transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

23 Sep 2020

Bioinformatics analysis reveals genes and pathways shared in COVID-19 disease and comorbidities

Using bioinformatics approaches, researchers have identified genes and pathways shared among patients with comorbidities and having severe COVID-19. The research is published on the preprint server bioRxiv in September 2020.

23 Sep 2020

A subunit SARS-CoV-2 vaccine may offer broader protection against virus

A new study published in the preprint server bioRxiv in September 2020 reports on the structure of this protein, as revealed by cryo-electron microscopy (cryoEM).

23 Sep 2020

Molecular dynamic simulations reveal detailed spike-ACE2 interactions

The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.

23 Sep 2020

Common genetic variants may influence susceptibility to COVID-19

Researchers in the United States and Japan have conducted a study suggesting that a commonly occurring genetic variant influences susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

23 Sep 2020

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020

Nanoparticle SARS-CoV-2 model could potentially speed the search for drugs

A team of scientists from the National Center for Advancing Translational Sciences and Naval Research Laboratory in Washington, D.C., has developed a new tool that mimics how SARS-CoV-2 -- the virus that causes COVID-19 -- infects a cell, information that could potentially speed the search for treatments against the disease.

22 Sep 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

New method isolates antibody-like proteins that capture and neutralize SARS-CoV-2

Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus - 4 of which also exhibited neutralizing activity - within 4 days, according to a new study.

19 Sep 2020

Adaptations found in RNA secondary structure in genes of two proteins of SARS-CoV-2

To investigate mutations in coronaviruses, a new study by scientists at Duke University and published on the preprint server bioRxiv, used a computational methodology, adaptiPhy, which identifies extra nucleotide substitutions in certain parts of the viral genome compared to mutations that have no effect on the genome.

18 Sep 2020

Genetic variants of human ACE2 are differentially recognized by SARS-CoV-2

Scientists at the University of Wisconsin reveals that the genetic variants of human angiotensin 2 (ACE2) receptors can have altered recognition by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. The study is currently available on the bioRxiv* preprint server.

18 Sep 2020

Researchers develop non-infectious nanoparticle probes to study SARS-CoV-2

Scientists and researchers at the U.S. Naval Research Laboratory and National Center for Advancing Translational Sciences, submitted their findings to ACS Nano, a monthly peer-reviewed scientific journal, on their collaboration to develop SARS-CoV-2 nanoparticle probes that are used to study fundamental interactions between SARS-CoV-2 Spike proteins and human cells.

18 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Key China COVID-19 study produced results that influenced subsequent research on coronavirus

Early in the onset of the COVID-19 pandemic, a small study in China produced results that influenced subsequent research on the virus.

18 Sep 2020

Study invalidates Ebselen and other broad-spectrum SARS-CoV-2 Mpro inhibitors

Other novel compounds with Mpro inhibitory activity have also been claimed to have antiviral activity. These include ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12. A new research paper discusses the role of these molecules as potential Mpro inhibitors in the prevention of SARS-CoV-2 infection.

18 Sep 2020

Study sheds new light on the mechanism of COVID-19 infection

The spike protein on the surface of the SARS-CoV-2 coronavirus can adopt at least ten distinct structural states, when in contact with the human virus receptor ACE2, according to research from the Francis Crick Institute published in Nature today.

18 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020